Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
ANIP
vs
S&P 500
ANIP
S&P 500
Over the past 12 months, ANIP has underperformed S&P 500, delivering a return of -23% compared to S&P 500's +11% growth.
Stocks Performance
ANIP vs S&P 500
Performance Gap
ANIP vs S&P 500
Performance By Year
ANIP vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
ANI Pharmaceuticals Inc
Glance View
ANI Pharmaceuticals makes and sells prescription medicines in the United States. Its business includes branded drugs, generic drugs, and a growing set of specialty and rare-disease treatments. It also manufactures some of its own products, which gives it more control over supply for medicines that can be hard to make reliably. The company sells mainly to pharmacies, wholesalers, hospitals, and other healthcare customers that distribute medicines to patients. It earns money when those customers buy its products, and in some cases through licensing or product rights tied to specific drugs. A large part of ANI’s business comes from medicines that have already been approved and are sold after the company takes over or develops the product. What makes ANI different is its focus on older, off-patent medicines and specialized pharmaceutical products rather than broad consumer healthcare. That means it competes through manufacturing know-how, regulatory expertise, and the ability to keep supplying drugs that still have steady medical demand. In simple terms, ANI is a drug maker that finds value in established medicines and the harder-to-manufacture products many larger pharma companies overlook.
